Innovaspain.com has dedicated an article to the research undertaken by Iproteos, a company specialized in the discovery of drugs for diseases of the nervous system. This spin-off company of IRB Barcelona has demonstrated the effectiveness of a novel compound, IPR-19, to reverse the cognitive deficit associated with schizophrenia in mouse models. At present, this peptide is in the preclinical phase.
Link to Innovaspain.com
Agencia SINC echoes the interest of pharmaceutical multinationals in Iproteos. Founded in 2011 by Teresa Tarragó, this biotechnology company is a spin-off of IRB Barcelona. Since then, Tarragó aimed to convert a molecule (IPR-19) discovered during her research into a drug. This molecule has great potential for the treatment of cognitive problems caused by schizophrenia.
Link to Agencia SINC
In an interview on the programme “Valencia en la Onda”, presented by Mª Paz Fernández on Radio Onda Cero, Meritxell Teixidó, research associate at IRB Barcelona, talks about his research at the Design, Synthesis and Structure of Peptides and Proteins Laboratory.
During the interview, Teixidó explains the Lab's work on transforming a protein from bee venom into a tool that helps treatments get inside the brain and can be applied to treat central nervous system diseases.
The Nigerian website "24Hours Naija News" devotes a report to the use of insects such as termites and grasshoppers in the treatment of cancer, diabetes, rheumatoid arthritis or Human Immuno-deficiency Virus (HIV).
The article includes a reference to the research on the use of wasp venom as a strategy to kill cancer cells selectively lead by Ernest Giralt, head of the Design, Synthesis and Structure of Peptides and Proteins Lab at IRB Barcelona.
Link to 24Hours Naija News
The newspaper “El Mundo” devotes an extensive report to Friedreich's Ataxia through the testimony of Marta, a 13-year-old girl, who began to show the first symptoms of this rare disease when she was only five years old.
The report highlights the research performed by IRB Barcelona aimed to develop an injectable frataxin treatment that can reach the brain. Frataxin is the protein that is reduced in those affected by this disease.
Meritxell Teixidó, the researcher behind the project, which also involves Macarena Sánchez and Ernest Giralt, stresses: "I believe that in 10 or 15years there will be a therapy that turns Friedreich's Ataxia into a chronic disease." And she adds, “...
The specialist publication The Pharmaceutical Journal devotes a feature article to the efforts being made by researchers worldwide to get drugs across the blood-brain barrier in order to treat central nervous system disorders such as Alzheimer’s disease, depression, and epilepsy. Among the scientists mentioned is Ernest Giralt and the work performed by his lab in search for peptides to be used as Trojan horses to smuggle drugs across the barrier.
The Pharmaceutical Journal, Vol 298, No 7901, online | DOI: 10.1211/PJ.2017.20202723...
ACCIÓ awards the Institute’s Innovation Department with the quality seal TECNIO and two VALUNI grants for technology transfer projects
"El Mundo" publishes an article about an IRB Barcelona research project funded by two patient associations, the international BabelFamily and Asogaf from Granada, that is devoted to finding a treatment for the neurodegenerative disease Friedreich's Ataxia.
Meritxell Teixidó and Macarena Sánchez, scientists behind the project, which also involves Ernest Giralt, explain that the "challenge is to transform it into a chronic disease; the dream would be to halt it or to slow down the degeneration".
Link to El Mundo
The newspaper "El Periódico" has reported on an IRB Barcelona research project on Friedreich’s ataxia disease, funded by the patient and family association, the Babel Family, and the Asociación Granadina de la Ataxia de Friedreich (ASOGAF). The disease is caused by a defect in a gene, frataxin, which results in reduced levels of this protein in the body, particularly affecting the brain, spinal cord and muscles.
The project aims to develop an injectable frataxin treatment that can reach the brain, "like the injection of insulin for diabetics", explains Ernest Giralt,...
High impact in the international media of Ernest Giralt's latest work presented at the meeting of the American Chemical Society in San Francisco. Giralt, head of the Design, Synthesis and Structure of Peptides and Proteins Lab at IRB Barcelona, is working on transforming a protein from bee venom into a tool that helps treatments get inside the brain.
“We thought that because the venoms of some animals are able to attack the central nervous system, they should be able to go through the blood-brain barrier and possibly shuttle drugs across it," explains Giralt.
Link to ...